9 
Hr. Silverman said Stauffer Qiemiced Ccnpany vould probably prefer to subnit 
information independently to each feder 2 d. agency requesting information, rather 
than to a "oentrad infontation clearing house." 
Dr. Hason questioned whether the risks eissociated with reoombinant CNA 
technology should be evaluated differently than those associated with 
other fermentation processes. Or. Bems felt this issue revolved around 
the definition of meaningful medical surveillance. Uhtil meaningful surveil- 
lance is defined, it is difficult to determine whether a ocmpany is effectively 
protecting the worker. He said Or. Philip Landrigan of NI06H had agreed to 
address the Large-Scale Review Qroup on NI06H determinations in the area of 
medical surveillance. 
The meeting was edjcurned at 4:00 p.m. 
Respectively subnitted 
Executive Secretary 
I hereby certify that, to the best of 
my knowledge, the foregoing Minutes are 
accurate and complete. 
Co-thaiman 
Large-Scale Review Working Gtoup 
of the Reccmbinant DNA Advisory Carmittee 
Date 
Co-Chairman 
Large-Scale Review Working Group 
of the Reoombinant DNA Advisory Corrmittee 
[ 189 ] 
